Why the Stock Price of This Cancer Screening Company Soared 17% Thursday

Abbott Laboratories agreed to buy cancer-screening specialist Exact Sciences for about $21 billion, paying $105 per share with the deal expected to close in Q2 next year; Exact, maker of Cologuard, reported $851 million in Q3 revenue and reiterated a full-year revenue guide of roughly $3.22–3.235 billion. Abbott framed the acquisition as a play into a U.S. cancer screening and precision oncology diagnostics market it estimates at about $60 billion (over $100 billion globally) that is projected to grow 6–8% annually, highlighting strategic exposure to a high-growth area of healthcare. Exact shares jumped about 17% to their highest close in four years (up ~80% YTD), while Abbott slipped nearly 2%; analysts note the rationale is sound but caution that the deal’s financing and high valuation will determine its ultimate attractiveness to Abbott shareholders.

Analysis

Abbott Laboratories announced a definitive agreement to acquire Exact Sciences for about $21 billion, valuing Exact at $105 per share with an expected close in the second quarter of next year. Exact Sciences reported $851 million in third-quarter revenue and raised its full-year revenue guidance to $3.22–$3.235 billion, and the company markets products such as Cologuard across a U.S. cancer screening and precision oncology diagnostics market Abbott estimates at roughly $60 billion (over $100 billion globally).

Market reaction shows a clear takeover premium for Exact: shares jumped ~17% to just under $101 and closed at a four-year high, up ~80% year-to-date; Abbott shares fell nearly 2% on the news and are up 10% YTD, trailing the S&P 500. Analysts cited in the article (Oppenheimer) view the strategic rationale as fundamentally sensible but flagged that the method of financing and the high valuation paid will be the primary determinants of long-term shareholder value for Abbott.

Given the scale and projected 6–8% annual growth of the screening market, the acquisition strengthens Abbott’s exposure to a high-growth healthcare segment, but integration execution, regulatory clearances and financing structure represent key near-term risks that will influence earnings dilution and leverage metrics.

Key Decisions for Investors

• Exact Sciences shareholders should consider the certainty of a $105-per-share cash deal and may lean toward realizing gains or tendering ahead of the expected Q2 closing given the clear takeover premium
• Abbott shareholders should demand disclosure of financing plans and model scenarios for debt issuance or equity dilution, since financing structure and the high valuation will materially affect EPS and leverage
• Monitor regulatory and integration milestones through Q2, as approvals or execution issues are the principal event risks that could alter the deal’s value proposition
• Investors seeking exposure to cancer-screening growth can view the sector favorably given the $60B U.S. (>$100B global) market and 6–8% growth projection, but should price in near-term M&A volatility and valuation risk